KR101148264B1 - 4-(4-아미노페닐)-3-모폴리논 제조 방법 - Google Patents

4-(4-아미노페닐)-3-모폴리논 제조 방법 Download PDF

Info

Publication number
KR101148264B1
KR101148264B1 KR1020067005136A KR20067005136A KR101148264B1 KR 101148264 B1 KR101148264 B1 KR 101148264B1 KR 1020067005136 A KR1020067005136 A KR 1020067005136A KR 20067005136 A KR20067005136 A KR 20067005136A KR 101148264 B1 KR101148264 B1 KR 101148264B1
Authority
KR
South Korea
Prior art keywords
morpholinone
aminophenyl
phenyl
nitrophenyl
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067005136A
Other languages
English (en)
Korean (ko)
Other versions
KR20060070561A (ko
Inventor
크리스티안 토마스
마티아스 버베
알렉산더 슈트라우브
Original Assignee
바이엘 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 파마 악티엔게젤샤프트 filed Critical 바이엘 파마 악티엔게젤샤프트
Publication of KR20060070561A publication Critical patent/KR20060070561A/ko
Application granted granted Critical
Publication of KR101148264B1 publication Critical patent/KR101148264B1/ko
Assigned to 바이엘 인텔렉쳐 프로퍼티 게엠베하 reassignment 바이엘 인텔렉쳐 프로퍼티 게엠베하 권리의 전부이전등록 Assignors: 바이엘 파마 악티엔게젤샤프트
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067005136A 2003-09-15 2004-09-09 4-(4-아미노페닐)-3-모폴리논 제조 방법 Expired - Lifetime KR101148264B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10342570A DE10342570A1 (de) 2003-09-15 2003-09-15 Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE10342570.5 2003-09-15
PCT/EP2004/010054 WO2005026135A1 (de) 2003-09-15 2004-09-09 Verfahren zur herstellung von 4-(4-aminophenyl)-3-morpholinon

Publications (2)

Publication Number Publication Date
KR20060070561A KR20060070561A (ko) 2006-06-23
KR101148264B1 true KR101148264B1 (ko) 2012-05-21

Family

ID=34305779

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067005136A Expired - Lifetime KR101148264B1 (ko) 2003-09-15 2004-09-09 4-(4-아미노페닐)-3-모폴리논 제조 방법

Country Status (22)

Country Link
US (1) US7598378B2 (https=)
EP (1) EP1664004B1 (https=)
JP (1) JP4852419B2 (https=)
KR (1) KR101148264B1 (https=)
CN (1) CN100430384C (https=)
AU (1) AU2004272255B2 (https=)
BR (1) BRPI0414382B1 (https=)
CA (1) CA2538906C (https=)
CY (1) CY1116644T1 (https=)
DE (1) DE10342570A1 (https=)
DK (1) DK1664004T3 (https=)
EG (1) EG26605A (https=)
ES (1) ES2545072T3 (https=)
HU (1) HUE025273T2 (https=)
IL (1) IL174194A (https=)
IN (1) IN2012DN00411A (https=)
MX (1) MXPA06002883A (https=)
PL (1) PL1664004T3 (https=)
PT (1) PT1664004E (https=)
SI (1) SI1664004T1 (https=)
WO (1) WO2005026135A1 (https=)
ZA (1) ZA200602093B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100898361B1 (ko) 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
US20120283434A1 (en) * 2010-01-04 2012-11-08 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
DE102010018299A1 (de) * 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
CA2810478A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one
AU2010362639B2 (en) 2010-10-18 2016-10-27 Apotex Pharmachem Inc. Processes for the preparation of Rivaroxaban and intermediates thereof
EP2697209B1 (en) 2011-04-11 2015-09-23 Sandoz AG Method for the preparation of substituted oxazolidinones
WO2012153155A1 (en) 2011-05-06 2012-11-15 Egis Gyógyszergyár Nyilvãnosan Müködö Részvény-Társaság Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
CN102320988B (zh) * 2011-06-03 2014-04-09 中国科学院上海有机化学研究所 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
CN103288814B (zh) * 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
IN2013MU01113A (https=) 2013-03-25 2015-06-19 Glenmark Generics Ltd
KR20140127651A (ko) * 2013-04-25 2014-11-04 주식회사 종근당 4-(4-아미노페닐)-3-모폴리논의 신규한 제조 방법
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
CN105980381A (zh) 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
CN103709116B (zh) * 2013-12-10 2015-09-23 四川大学 一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法
CN103755657B (zh) * 2013-12-25 2015-10-14 湖南方盛制药股份有限公司 一种利伐沙班中间体的制备方法
CN104974059B (zh) * 2014-04-14 2016-11-16 北大方正集团有限公司 一种利伐沙班中间体及其制备方法
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
EP3186246A1 (en) 2014-08-25 2017-07-05 Cipla Limited Process for the preparation of rivaroxaban
CN104478820B (zh) * 2014-12-22 2016-08-31 杭州瀚康生物医药科技有限公司 一种利伐沙班中间体的制备方法
CN104817548B (zh) * 2015-03-19 2017-12-01 郑州轻工业学院 一种对氢氧化锂、氢氧化钠、氢氧化钾可视化选择性识别的有机小分子
HU231119B1 (hu) 2018-01-12 2020-11-30 Richter Gedeon Nyrt. Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
CN109651287A (zh) * 2019-01-18 2019-04-19 吕东 一种4-(4-氨基苯基)吗啉酮的制备方法
US12168167B2 (en) * 2023-01-11 2024-12-17 Kenneth W. Rittmann Golf club head cover device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047919A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
JPH10503768A (ja) * 1994-08-02 1998-04-07 メルク シヤープ エンド ドーム リミテツド アゼチジン、ピロリジンおよびピペリジン誘導体
EP0912175A4 (en) * 1996-06-28 1999-09-08 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
EP1479676A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Benzimidazole-derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047919A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Also Published As

Publication number Publication date
AU2004272255A1 (en) 2005-03-24
EP1664004A1 (de) 2006-06-07
DK1664004T3 (en) 2015-09-07
SI1664004T1 (sl) 2015-10-30
PL1664004T3 (pl) 2015-11-30
CY1116644T1 (el) 2017-03-15
US7598378B2 (en) 2009-10-06
WO2005026135A1 (de) 2005-03-24
CN1852902A (zh) 2006-10-25
BRPI0414382A (pt) 2006-11-21
US20070066611A1 (en) 2007-03-22
JP2007505821A (ja) 2007-03-15
JP4852419B2 (ja) 2012-01-11
CN100430384C (zh) 2008-11-05
BRPI0414382B1 (pt) 2014-01-28
HUE025273T2 (en) 2016-02-29
IN2012DN00411A (https=) 2015-08-21
CA2538906A1 (en) 2005-03-24
MXPA06002883A (es) 2006-06-05
CA2538906C (en) 2013-04-23
IL174194A0 (en) 2006-08-01
DE10342570A1 (de) 2005-04-14
IL174194A (en) 2010-11-30
HK1098134A1 (zh) 2007-07-13
EP1664004B1 (de) 2015-06-24
EG26605A (en) 2014-03-23
PT1664004E (pt) 2015-09-21
KR20060070561A (ko) 2006-06-23
ES2545072T3 (es) 2015-09-08
ZA200602093B (en) 2007-05-30
AU2004272255B2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
KR101148264B1 (ko) 4-(4-아미노페닐)-3-모폴리논 제조 방법
KR101630884B1 (ko) 모르폴린 유도체의 제조
JP5285652B2 (ja) モルホリン誘導体の化学合成
CN119080775A (zh) 他达那非的制备方法
JPS638368A (ja) ４−ベンジロキシ−３−ピロリン−２−オン−１−イルアセトアミド、その製造方法および使用方法
JPH04169583A (ja) フェノチアジン誘導体およびその製造方法
CN111187223B (zh) 利拉利汀中间体2-氯甲基-4-甲基喹唑啉的合成方法
HK1098134B (en) Method for the production of 4-(4-aminophenyl)-3-morpholinon
CN104402860A (zh) 甲磺酸伊马替尼中间体的制备方法
JPH11322725A (ja) １，３，４―三置換１，２，４―トリアゾリウム塩の製法及びこのような塩
JP2007528385A (ja) オキシカルバゼピンの製造方法
JP2026512555A (ja) ４－クロロピロロピリミジンアナログ化合物またはその派生物の合成方法
JPH11310558A (ja) ２―アミノ―４，５，３’，４’―テトラメトキシベンゾフェノンの製造方法
CN103626630B (zh) 利伐沙班中间体及其制备方法
CN118324683A (zh) 一种3-氯-2-氧代-[1,3']双吡咯烷基-1'-羧酸烯丙基酯的制备方法
CN115925636A (zh) 一种工业化生产2-巯基-5-甲氧基苯并咪唑的方法
CN114890953A (zh) 一种2-氨甲基嘧啶盐酸盐的制备方法
KR20100088870A (ko) 3,4-디히드로퀴나졸린-4-온 유도체의 새로운 제조방법
JPH04321659A (ja) Ｎ，ｎ−ジヒドロカルビルヒドロキシルアミンの製造方法
JPS6323867A (ja) テトラヒドロキノロンエ−テル類の新規製造法
JPS6143169A (ja) ２−クロロベンズイミダゾ−ル誘導体の製造法
JPWO1998032736A1 (ja) ベンジルコハク酸誘導体の製造方法
JP2002047253A (ja) ２，２−ビス（３−ニトロ−４−ヒドロキシフェニル）プロパンの製造方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060314

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20090825

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090828

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110608

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120221

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120514

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120514

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150430

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150430

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160427

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160427

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170504

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170504

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180427

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180427

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190429

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190429

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210428

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20240430

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20250309

Termination category: Expiration of duration